Virgin Galactic Announces Third Quarter 2021 Financial Results
Virgin Galactic Holdings (NYSE: SPCE) reported third quarter 2021 results, highlighting strong demand for its commercial space travel service, with approximately 700 of the 1,000 targeted reservations sold at a price of $450,000 per seat. The company is on track to commence private astronaut services in Q4 2022 and has initiated a fleet enhancement program to boost vehicle reliability. Financially, Virgin Galactic maintains a robust cash position of $1 billion, though it recorded a net loss of $48 million, an improvement from a $92 million loss the previous year.
- Strong demand for space travel with 700 of 1,000 targeted reservations sold.
- Cash position remains strong at approximately $1 billion.
- Improvement in net loss from $92 million in Q3 2020 to $48 million in Q3 2021.
- Net loss of $48 million indicates ongoing financial challenges.
- GAAP selling, general, and administrative expenses increased to $50 million.
- Commercial Service on Track for Q4 2022
-
Strong Ticket Sales at Updated Pricing of
per Seat$450,000 - Demonstrates Value of Differentiated Community Experience
-
Commenced Fleet Enhancement Program to Increase
Flight Rate and Extend Vehicle Service Life Ahead of Commercial Launch
“We are entering our fleet enhancement period with a clear roadmap for increasing the durability, reliability and predictability of our vehicles in preparation for commercial service next year,” said
Business Highlights:
- Expected start of private astronaut commercial service on track for Q4 2022.
-
On
July 11, 2021 , successfully completed first fully crewed spaceflight, Unity 22. The flight fulfilled several test objectives including evaluating the cabin and customer experience. The livestream was watched by tens of millions around the world and brought in tens of thousands of requests for information on futureVirgin Galactic spaceflights. -
In
August 2021 , opened sales to our Spacefarer community, the group of early hand-raisers who had reserved the right to be first in line for tickets. The Company announced a target of 1,000 reservations prior to the launch of private astronaut commercial service. Approximately 700 of these 1,000 have been sold to date. Current pricing of per seat has been well received.$450,000 -
On
October 14, 2021 , announced the beginning of planned vehicle enhancement period. This program will increase vehicle service life and flight-rate capability in preparation for commercial service. -
In
October 2021 , the Company entered into a lease agreement for a new design and collaboration center where the next generation vehicles will be designed and engineered.
Third Quarter 2021 Financial Highlights:
-
Cash position remains strong at approximately
, which includes cash and cash equivalents of$1.0 billion and marketable securities of$721 million as of$286 million September 30, 2021 . -
In
July 2021 , the Company completed an “at-the-market” equity offering program (the “ATM Offering”). In connection with the ATM Offering, the Company filed a prospectus supplement with theU.S. Securities and Exchange Commission to offer and sell up to of shares of the Company’s common stock from time to time. The Company ultimately generated$500 million in gross proceeds through the sale of approximately 13.7 million shares of common stock. The Company intends to use the net proceeds generated from the ATM Offering for general corporate purposes, with a priority on expansion of its spaceship fleet.$500 million -
GAAP selling, general, and administrative expenses of
, compared to$50 million in the third quarter of 2020. Non-GAAP selling, general and administrative expenses of$31 million in the third quarter of 2021, compared to$40 million in the third quarter of 2020.$24 million -
GAAP research and development expenses of
, compared to$36 million in the third quarter of 2020. Non-GAAP research and development expenses of$46 million in the third quarter of 2021, compared to$31 million in the third quarter of 2020.$41 million -
Adjusted EBITDA totaled
, compared to$(68) million in the third quarter of 2020.$(66) million -
Net loss of
, compared to a$48 million net loss in the third quarter of 2020.$92 million -
Cash paid for capital expenditures totaled
, compared to$1 million in the third quarter of 2020.$4 million
Conference Call Information
About
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws with respect to
Third Quarter 2021 Financial Results
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited and in thousands except for per share data) |
||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
(As restated) |
|
|
|
(As restated) |
||||||||
Revenue |
|
$ |
2,580 |
|
|
$ |
— |
|
|
$ |
3,151 |
|
|
$ |
238 |
|
Cost of revenue |
|
207 |
|
|
— |
|
|
270 |
|
|
173 |
|
||||
Gross profit |
|
2,373 |
|
|
— |
|
|
2,881 |
|
|
65 |
|
||||
Selling, general, and administrative expenses |
|
49,859 |
|
|
30,936 |
|
|
133,276 |
|
|
83,738 |
|
||||
Research and development expenses |
|
35,593 |
|
|
46,075 |
|
|
107,859 |
|
|
117,276 |
|
||||
Operating loss |
|
(83,079 |
) |
|
(77,011 |
) |
|
(238,254 |
) |
|
(200,949 |
) |
||||
Change in fair value of warrants |
|
34,432 |
|
|
(15,280 |
) |
|
(34,650 |
) |
|
(341,772 |
) |
||||
Interest income, net |
|
234 |
|
|
313 |
|
|
766 |
|
|
1,979 |
|
||||
Other income (loss), net |
|
70 |
|
|
(44 |
) |
|
110 |
|
|
5 |
|
||||
Loss before income taxes |
|
(48,343 |
) |
|
(92,022 |
) |
|
(272,028 |
) |
|
(540,737 |
) |
||||
Income tax expense |
|
(25 |
) |
|
(40 |
) |
|
(74 |
) |
|
(34 |
) |
||||
Net loss |
|
(48,368 |
) |
|
(92,062 |
) |
|
(272,102 |
) |
|
(540,771 |
) |
||||
Other comprehensive loss: |
|
|
|
|
|
|
|
|
||||||||
Foreign currency translation adjustment |
|
3 |
|
|
48 |
|
|
11 |
|
|
(6 |
) |
||||
Unrealized loss on marketable securities |
|
(437 |
) |
|
— |
|
|
(437 |
) |
|
— |
|
||||
Total comprehensive loss |
|
$ |
(48,802 |
) |
|
$ |
(92,014 |
) |
|
$ |
(272,528 |
) |
|
$ |
(540,777 |
) |
|
|
|
|
|
|
|
|
|
||||||||
Net loss per share: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
(0.19 |
) |
|
(0.41 |
) |
|
(1.11 |
) |
|
(2.54 |
) |
||||
Diluted |
|
(0.32 |
) |
|
(0.41 |
) |
|
(1.11 |
) |
|
(2.54 |
) |
||||
|
|
|
|
|
|
|
|
|
||||||||
Weighted-average shares outstanding: |
|
|
|
|
|
|
|
|
||||||||
Basic |
|
254,749,195 |
|
|
225,253,536 |
|
|
244,157,923 |
|
|
213,193,386 |
|
||||
Diluted |
|
255,147,228 |
|
|
225,253,536 |
|
|
244,157,923 |
|
|
213,193,386 |
|
Condensed Consolidated Balance Sheets (In thousands, except share data) |
||||||||
|
|
|
|
|
||||
|
|
(Unaudited) |
|
(As restated) |
||||
Assets |
|
|
|
|
||||
Current assets |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
702,565 |
|
|
$ |
665,924 |
|
Restricted cash |
|
18,078 |
|
|
13,031 |
|
||
Marketable securities, short-term |
|
29,441 |
|
|
— |
|
||
Inventories |
|
29,306 |
|
|
30,483 |
|
||
Prepaid expenses and other current assets |
|
8,963 |
|
|
18,489 |
|
||
Total current assets |
|
788,353 |
|
|
727,927 |
|
||
Marketable securities, long-term |
|
256,691 |
|
|
— |
|
||
Property, plant, and equipment, net |
|
48,130 |
|
|
53,148 |
|
||
Other non-current assets |
|
24,449 |
|
|
22,915 |
|
||
Total assets |
|
$ |
1,117,623 |
|
|
$ |
803,990 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
||||
Current liabilities |
|
|
|
|
||||
Accounts payable |
|
$ |
7,997 |
|
|
$ |
5,998 |
|
Accrued expenses |
|
23,298 |
|
|
22,982 |
|
||
Customer deposits |
|
84,769 |
|
|
83,211 |
|
||
Other current liabilities |
|
2,416 |
|
|
2,830 |
|
||
Total current liabilities |
|
118,480 |
|
|
115,021 |
|
||
Non-current liabilities |
|
|
|
|
||||
Warrant liability |
|
— |
|
|
135,440 |
|
||
Other long-term liabilities |
|
29,214 |
|
|
26,451 |
|
||
Total liabilities |
|
$ |
147,694 |
|
|
$ |
276,912 |
|
Stockholders' Equity |
|
|
|
|
||||
Preferred stock, |
|
$ |
— |
|
|
$ |
— |
|
Common stock, |
|
25 |
|
|
23 |
|
||
Additional paid-in capital |
|
2,013,171 |
|
|
1,297,794 |
|
||
Accumulated deficit |
|
(1,042,846 |
) |
|
(770,744 |
) |
||
Accumulated other comprehensive income |
|
(421 |
) |
|
5 |
|
||
Total stockholders' equity |
|
969,929 |
|
|
527,078 |
|
||
Total liabilities and stockholders' equity |
|
$ |
1,117,623 |
|
|
$ |
803,990 |
|
Condensed Consolidated Statements of Cash Flows (Unaudited and in thousands) |
||||||||
|
|
Nine Months Ended |
||||||
|
|
2021 |
|
2020 |
||||
|
|
|
|
(As restated) |
||||
Cash flows from operating activities |
|
|
|
|
||||
Net loss |
|
$ |
(272,102 |
) |
|
$ |
(540,771 |
) |
Stock-based compensation |
|
48,704 |
|
|
18,575 |
|
||
Depreciation and amortization |
|
8,635 |
|
|
6,998 |
|
||
Change in fair value of warrant liability |
|
34,650 |
|
|
341,772 |
|
||
Other operating activities, net |
|
(42 |
) |
|
75 |
|
||
Change in assets and liabilities |
|
|
|
|
||||
Inventories |
|
1,178 |
|
|
1,195 |
|
||
Other current and non-current assets |
|
6,342 |
|
|
6,152 |
|
||
Accounts payable and accrued expenses |
|
1,824 |
|
|
719 |
|
||
Customer deposits |
|
2,148 |
|
|
(172 |
) |
||
Other current and non-current liabilities |
|
3,026 |
|
|
2,394 |
|
||
Net cash used in operating activities |
|
(165,637 |
) |
|
(163,063 |
) |
||
Cash flows from investing activity |
|
|
|
|
||||
Capital expenditures |
|
(2,452 |
) |
|
(13,661 |
) |
||
Purchases of marketable securities |
|
(286,132 |
) |
|
— |
|
||
Cash used in investing activity |
|
(288,584 |
) |
|
(13,661 |
) |
||
Cash flows from financing activities |
|
|
|
|
||||
Payments of finance lease obligations |
|
(105 |
) |
|
(89 |
) |
||
Proceeds from issuance of common stock pursuant to stock options exercised |
|
18,856 |
|
|
— |
|
||
Payment of notes payable |
|
(310 |
) |
|
— |
|
||
Proceeds from issuance of common stock |
|
500,000 |
|
|
460,200 |
|
||
Transaction costs |
|
(6,753 |
) |
|
(20,866 |
) |
||
Withholding taxes paid on behalf of employees on net settled stock-based awards |
|
(15,779 |
) |
|
(399 |
) |
||
Net cash provided by (used in) by financing activities |
|
495,909 |
|
|
438,846 |
|
||
Net increase in cash and cash equivalents |
|
41,688 |
|
|
262,122 |
|
||
Cash, cash equivalents and restricted cash at beginning of period |
|
678,955 |
|
|
492,721 |
|
||
Cash, cash equivalents and restricted cash at end of period |
|
$ |
720,643 |
|
|
$ |
754,843 |
|
|
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
702,565 |
|
|
$ |
741,575 |
|
Restricted cash |
|
18,078 |
|
|
13,268 |
|
||
Cash, cash equivalents and restricted cash |
|
$ |
720,643 |
|
|
$ |
754,843 |
|
Use of Non-GAAP Financial Measures (Unaudited)
This press release references certain non-GAAP financial measures, including adjusted EBITDA, non-GAAP selling, general, and administrative expense and non-GAAP research and development expense. The Company defines adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization, stock-based compensation, and certain other items the Company believes are not indicative of its core operating performance. It defines non-GAAP selling, general, and administrative expenses as selling, general, and administrative expenses other than stock-based compensation and non-capitalized transaction costs, and non-GAAP research and development expenses as research and development expenses other than stock-based compensation. None of these non-GAAP financial measures is a substitute for or superior to measures of financial performance prepared in accordance with generally accepted accounting principles in
The Company believes that presenting these non-GAAP financial measures provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational-decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.
A reconciliation of adjusted EBITDA to net loss for the three and nine months ended
Amounts in thousands ($) |
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
Net Loss |
|
$ |
(48,368 |
) |
|
$ |
(92,062 |
) |
|
$ |
(272,102 |
) |
|
$ |
(540,771 |
) |
Income tax expense |
|
25 |
|
|
40 |
|
|
74 |
|
|
34 |
|
||||
Interest expense |
|
6 |
|
|
9 |
|
|
19 |
|
|
26 |
|
||||
Depreciation & amortization |
|
2,895 |
|
|
2,509 |
|
|
8,635 |
|
|
6,998 |
|
||||
Non-capitalized transaction costs* |
|
— |
|
|
— |
|
|
— |
|
|
697 |
|
||||
Stock-based compensation |
|
12,169 |
|
|
8,625 |
|
|
48,704 |
|
|
18,575 |
|
||||
Change in fair value of warrants |
|
(34,432 |
) |
|
15,280 |
|
|
34,650 |
|
|
341,772 |
|
||||
Adjusted EBITDA |
|
$ |
(67,705 |
) |
|
$ |
(65,599 |
) |
|
$ |
(180,020 |
) |
|
$ |
(172,669 |
) |
A reconciliation of selling, general, and administrative expenses to non-GAAP selling, general, and administrative expenses for the three and nine months ended
Amounts in thousands ($) |
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
Selling, general, and administrative expenses |
|
49,859 |
|
|
30,936 |
|
|
133,276 |
|
|
83,738 |
|
||||
Stock-based compensation |
|
8,540 |
|
|
5,056 |
|
|
37,004 |
|
|
11,472 |
|
||||
Non-capitalized transaction costs* |
|
— |
|
|
— |
|
|
— |
|
|
697 |
|
||||
Depreciation & amortization |
|
1,592 |
|
|
1,448 |
|
|
4,774 |
|
|
3,809 |
|
||||
Non-GAAP selling, general, and administration expenses |
|
$ |
39,727 |
|
|
$ |
24,432 |
|
|
$ |
91,498 |
|
|
$ |
67,760 |
|
A reconciliation of research and development expenses to non-GAAP research and development expenses for the three and nine months ended
Amounts in thousands ($) |
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
Research and development expenses |
|
35,593 |
|
|
46,075 |
|
|
107,859 |
|
|
117,276 |
|
||||
Stock-based compensation |
|
3,629 |
|
|
3,570 |
|
|
11,700 |
|
|
7,103 |
|
||||
Depreciation & amortization |
|
1,304 |
|
|
1,156 |
|
|
3,861 |
|
|
3,189 |
|
||||
|
|
$ |
30,660 |
|
|
$ |
41,349 |
|
|
$ |
92,298 |
|
|
$ |
106,984 |
|
_____________
∗ Non-capitalized transaction costs include non-recurring expenses related to preparation and filing of an S-1 registration statement in the first quarter of 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005984/en/
For investor relations inquiries:
seth.zaslow@virgingalactic.com
For media inquiries:
Aleanna Crane – Vice President, Communications
aleanna.crane@virgingalactic.com
Source:
FAQ
What are the financial results for Virgin Galactic in Q3 2021?
When does Virgin Galactic expect to start commercial space services?
What is the current price for a seat on Virgin Galactic's spaceflights?
How many reservations has Virgin Galactic sold for its spaceflights?